Last reviewed · How we verify
Cornea tissue transplant
At a glance
| Generic name | Cornea tissue transplant |
|---|---|
| Sponsor | Case Western Reserve University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years (NA)
- The Belgian Endothelial Surgical Transplant of the Cornea (NA)
- Plasma Rich in Growth Factors in Corneal Endothelial Transplantation (NA)
- Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft (PHASE1, PHASE2)
- The German Keratoplasty Registry of the German Ophthalmological Society (DOG)
- A Clinical Study on Co-transplantation of Autologous Limbal Stem Cells and Corneal Stromal Stem Cells to Repair Corneal Injury (PHASE1, PHASE2)
- Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting (NA)
- Pathogenetic Risk Factors for Corneal Graft Rejection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cornea tissue transplant CI brief — competitive landscape report
- Cornea tissue transplant updates RSS · CI watch RSS
- Case Western Reserve University portfolio CI